Article Details

Spark Therapeutics (NASDAQ:ONCE) Earns Buy Rating from Analysts at Guggenheim

Retrieved on: 2018-11-03 14:21:48

Tags for this article:

Click the tags to see associated articles and topics

Spark Therapeutics (NASDAQ:ONCE) Earns Buy Rating from Analysts at Guggenheim. View article details on hiswai:

Excerpt

<div><b>Sofinnova Ventures</b> Inc purchased a new stake in Spark Therapeutics during the 1st quarter worth about $32,048,000. Partner Fund Management L.P. ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up